How can we remove barriers to HIV testing outside of a GUM setting?

HIV testing. Br J Gen Pract (2008) 0.75

HIV testing. Br J Gen Pract (2008) 0.75

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med (2003) 8.05

Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30

Genitourinary medicine clinic and general practitioner contact: what do patients want? Sex Transm Infect (2007) 1.18

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Human immunodeficiency virus infection and fertility care in the United Kingdom: demand and supply. Fertil Steril (2006) 3.55

Contraception and HIV: what do we know and what needs to be done? J Fam Plann Reprod Health Care (2006) 2.64

Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage (2005) 1.51

Implanon failure and antiretroviral therapy. J Fam Plann Reprod Health Care (2008) 1.39

Use of chaperones in general practice: chaperones protect both parties. BMJ (2005) 1.38

When good news is bad news: psychological impact of false positive diagnosis of HIV. AIDS Care (2008) 1.19

British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med (2011) 1.17

Dolutegravir for treatment of HIV: SPRING forwards? Lancet (2013) 0.79

Response to Waters et al. 'Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml'. AIDS (2006) 0.75

Dr McCartney is right, the BMA is wrong. BMJ (2011) 0.75

Does chronic stress lead to increased rates of recurrences of genital herpes--a review of the psychoneuroimmunological evidence? Int J STD AIDS (2008) 0.75

HPV vaccination--reaping the rewards of the appliance of science. BMJ (2013) 0.75

Setting standards for the development and use of complementary and alternative therapies in herpes. Herpes (2005) 0.75

Letter: comments for consideration by the facial lipoatrophy panel. Dermatol Surg (2007) 0.75

Audit unlocked. Sex Transm Infect (2013) 0.75

The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection. AIDS (2009) 0.75

Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. AIDS (2016) 0.75

Highlights from the 9th IAS Conference on HIV Science, 23-26 July 2017, Paris, France. J Virus Erad (2017) 0.75

How to use information technology in the clinic to improve patient experience. Sex Transm Infect (2016) 0.75

Successful management of viral infections and other dermatoses with imiquimod 5% cream. Acta Derm Venereol Suppl (Stockh) (2003) 0.75